Clinical trials: Stage IB Ovarian Cancer
Ovarian Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
- Trial name
- NCT03704467
- Testing
- M6620, Avelumab, Carboplatin
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other…
- Conditions
- Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
- Trial name
- NCT01941316
- Testing
- Carfilzomib, Irinotecan
- Where
- 8 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum…
- Trial name
- NCT02098343
- Testing
- APR-246, Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
- Where
- 55 sites in United States, Belgium and 6 more
- Volunteers
- 247 people
- Sponsor
- Aprea Therapeutics
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination.
- Trial name
- CHARGE (NCT04315233)
- Testing
- Ribociclib, Belinostat
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Estrogen Receptor Positive, HER2/Neu Negative
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- NCT01928186
- Testing
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen.
- Conditions
- Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- SOFT (NCT00066690)
- Testing
- Exemestane, Laboratory Biomarker Analysis, Oophorectomy
- Where
- 500 sites in United States, Canada and 1 more
- Volunteers
- 3,066 people
- Sponsor
- ETOP IBCSG Partners Foundation
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer.
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT05276973
- Testing
- Biopsy Procedure, Carboplatin, Ipatasertib
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab)…
- Trial name
- NCT01708161
- Testing
- BYL719, AMG 479
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
This randomized phase II trial studies OPT-821 and vaccine therapy to see how well they work compared with OPT-821 alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer that has…
- Conditions
- Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer
- Trial name
- NCT00857545
- Testing
- Laboratory Biomarker Analysis, Polyvalent Antigen-KLH Conjugate Vaccine, Saponin-based Immunoadjuvant OBI-821
- Where
- 46 sites in United States
- Volunteers
- 171 people
- Sponsor
- Gynecologic Oncology Group
COL6A3 Positive, HLA-A*0201 Positive Cells Present
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
This phase I/Ib trial studies the side effects and best dose of utomilumab and how well it works with CD8-positive T-lymphocyte (T-cell infusion) and aldesleukin in treating patients with ovarian cancer that has come back.
- Conditions
- COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive, Recurrent Ovarian Carcinoma
- Trial name
- NCT03318900
- Testing
- Aldesleukin, CD8-Positive T-Lymphocyte, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis…
- Trial name
- TEACO (NCT00296816)
- Testing
- Bevacizumab (Avastin®), Docetaxel (Taxotere®), Oxaliplatin (Eloxatin®)
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Sanofi
Ovarian Cancer
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
The purpose of this study was to determine the maximum tolerated dose (MTD)/recommended Phase II dose of lenvatinib administered in combination with carboplatin and gemcitabine (Phase IB) and to evaluate the safety and…
- Trial name
- NCT01133756
- Testing
- Lenvatinib, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Eisai Inc.
Ovarian Cancer
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary…
- Trial name
- NCT02389985
- Testing
- CRLX101, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- NewLink Genetics Corporation
Solid Tumors
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
The purpose of this study is to determine the safety and tolerability of ME-344 when given in combination with Hycamtin® in patients with solid tumors
- Trial name
- NCT02100007
- Testing
- ME-344, Topotecan
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 46 people
- Sponsor
- MEI Pharma, Inc.
Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as…
- Conditions
- Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT01081262
- Testing
- Bevacizumab, Capecitabine, Carboplatin
- Where
- 248 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Carcinoma, Soft Tissue Sarcoma
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
A phase Ib trial study of trabectedin when prescribed in combination with durvalumab in locally advanced/unresectable soft-tissue sarcoma and ovarian carcinomas.
- Trial name
- TRAMUNE (NCT03085225)
- Testing
- Combination of trabectedin with durvalumab
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Institut Bergonié
Cervical Carcinoma, Endometrioid Adenocarcinoma
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
This phase I trial studies the side effects and best dose of adavosertib when given together with external beam radiation therapy and cisplatin in treating patients with cervical, vaginal, or uterine cancer.
- Conditions
- Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma
- Trial name
- NCT03345784
- Testing
- Adavosertib, Cisplatin, External Beam Radiation Therapy
- Where
- 8 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
The purpose of this study is to evaluate giving chemotherapy drugs directly into the abdomen (belly) along with intravenous administration.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- NCT00582205
- Testing
- Paclitaxel, Cisplatin IP
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Oklahoma
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00470366
- Testing
- pegfilgrastim, cisplatin, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center